Atorvostatin 80 mg vs 10 mg in stable CHD. Any real benefit?

This time the full TNT study is anlayzed at Paper Shredder.

See also a shredding of the subanalysis with regards to diabetics.

Jupiter Study

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M Ridker, M.D. et al (click here for full article)
Methods: randomly assigned 17,802 healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo.

Results: Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001)
Figure 1: endpoint data

Figure 2: hazard ratio